Summary:
In patients with poorly controlled type 2 diabetes, treatment with LY3298176, a novel dual GIP and GLP-1 receptor agonist significantly improved glycemic control and reduced body weight compared to placebo and dulaglutide (GLP-1 receptor agonist), though it was associated with gastrointestinal adverse events such as nausea and vomiting.
| PICO | Description |
|---|---|
| Population | Adults with poorly controlled type 2 diabetes inadequately managed by diet, exercise, and standard therapies. |
| Intervention | LY3298176, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, administered at varying doses. |
| Comparison | Placebo and dulaglutide, a selective GLP-1 receptor agonist, used as active comparator. |
| Outcome | LY3298176 significantly improved HbA1c reductions and resulted in greater weight loss compared to placebo and dulaglutide. However, it was associated with increased gastrointestinal side effects including nausea and vomiting. |
Source: Juan Pablo Frias, et al. “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.” Read article here.
